Cytocom, Inc.
CBLI · NASDAQ
12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | |
|---|---|---|---|---|
| Market Cap | $43 | $7 | $11 | $45 |
| - Cash | $2 | $1 | $4 | $4 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $41 | $6 | $8 | $41 |
| Revenue | $0 | $1 | $1 | $2 |
| % Growth | -76.4% | -2.2% | -41.6% | – |
| Gross Profit | $0 | $1 | $1 | $2 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$2 | -$3 | -$4 | -$10 |
| % Margin | -907.8% | -236.5% | -315.7% | -497.1% |
| Net Income | -$2 | -$3 | -$4 | -$10 |
| % Margin | -912.2% | -237.7% | -317.3% | -498.2% |
| EPS Diluted | -0.19 | -0.23 | -0.32 | -0.87 |
| % Growth | 17.4% | 28.1% | 63.2% | – |
| Operating Cash Flow | -$2 | -$3 | -$5 | -$7 |
| Capital Expenditures | $0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$2 | -$3 | -$5 | -$7 |